Skip to content
Govbase
Govbase
Congress·In Committee·S. 3064

Congress Targets Lower Medicare Drug Costs and Fewer Hurdles for Some Non-Opioid Chronic Pain Meds

Relief of Chronic Pain Act of 2025

5 months ago·View on Congress.gov
⏸

Stalled

No legislative action in over 90 days.

Legislative Progress

Senate
House
President
Law

Key Points

  • Starting Jan. 1, 2026, Medicare Part D plans would have to waive the deductible for certain qualifying non-opioid chronic pain drugs.
  • These qualifying drugs would have to be put on the plan’s lowest cost-sharing tier, meaning patients should pay less out of pocket.
  • The bill bars Medicare drug plans from requiring people to try an opioid first before they can get these qualifying non-opioid drugs.
  • The bill also bans prior authorization for these qualifying non-opioid drugs, which could reduce delays and paperwork for patients and doctors.
  • It applies only to specific chronic pain conditions listed in the bill, like fibromyalgia, neuropathic pain, and diabetic nerve pain lasting over 3 months.
HealthcareMedicare MedicaidPrescription DrugsDrug Policy

Impact Analysis

Personal Impact

How this policy affects specific groups of people

Positive Impacts(1)
Medicare
Helps

Milestones

2 milestones2 actions
Oct 28, 2025Senate

Read twice and referred to the Committee on Finance.

Oct 28, 2025

Introduced in Senate

What Happens Next

Projected impacts based on AI analysis

Around the start of the 2026 plan year

Plans update their 2026 drug lists and pharmacy cost-sharing to comply with the new rules

If you take pain medicines, it becomes important to check your 2026 plan documents to see whether your drug meets the bill’s “qualifying” definition and what your new pharmacy price will be.

Source Information

Document Type

Congressional Bill

Official Title

Relief of Chronic Pain Act of 2025

Bill NumberS 3064
Congress119th Congress
ChamberSenate
Latest ActionRead twice and referred to the Committee on Finance.

Sponsor

Cosponsors

(1)
D: 1

Analysis generated by AI. Always verify with official sources.